Pfizer Gets Fast-Track Status For Muscular Dystrophy Therapy

Pfizer Gets Fast-Track Status For Muscular Dystrophy Therapy

Pfizer's battle with Sarepta Therapeutics in developing treatments for Duchenne muscular dystrophy is heating up, with Pfizer announcing the FDA will fast-track review of its gene therapy.